ADPT Stock — Adaptive Biotechnologies Corporation: Cash, EV, Pipeline

Share price

$28.61

Market cap

$4,566.0M

Cash

$344.3M

Enterprise value

$4,221.7M

Balance sheet

Cash	$344.3M
Debt	$0.0M
Net cash	$344.3M
Enterprise value	$4,221.7M
Basic shares	159.1M shares
Fully diluted shares	201.8M shares
Fully diluted market cap	$5,773.2M
Cash per share	$2.16

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ADPT daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 12 - Jul 24	Intervention B Vilazodone Hydrochloride (HCl)	Phase 2	Post Traumatic Stress Disorder	—
Jul 13 - Aug 24	Regorafenib	Phase 3	Glioblastoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

clonoSEQ

Approved · Active Modality: NGS-based diagnostic assay

Aliases clonoSEQ

Indications

multiple myeloma (MRD detection) (Approved)
B-cell acute lymphoblastic leukemia (ALL) (Approved)
chronic lymphocytic leukemia (CLL) (Approved)

Status note FDA-cleared MRD assay; only FDA-cleared MRD assay for multiple myeloma. Used in 180+ active biopharma trials. Company announced June 2026 intent to pursue separation of MRD and Immune Medicine businesses.

TCR-depleting antibody program

Preclinical · Active Modality: antibody

Target TCR (T-cell receptor)

Indications

ankylosing spondylitis (Preclinical)

Status note Per 10-K business section, company completed a preclinical data package for the TCR-depleting antibody program in ankylosing spondylitis.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Temozolomide
Lead indication	Glioblastoma
Lead phase	Phase 3
Active trials	3
Collaborator trials	7

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT03970447	Phase 3	Recruiting	Sponsor	ADPT	AZN	Glioblastoma	—
NCT05948579	Phase 2	Not yet recruiting	Sponsor	ADPT	—	Post Traumatic Stress Disorder	—
NCT05255354	Not disclosed	Recruiting	Sponsor	ADPT	—	Follicular Lymphoma; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma	—
NCT02735707	Phase 3	Recruiting	Collaborator	UMC Utrecht	—	Community-acquired Pneumonia, Influenza, COVID-19	—
NCT04419519	Phase 2	Active, not recruiting	Collaborator	Memorial Sloan Kettering Cancer Center	—	Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)	—
NCT06557330	Phase 2	Not yet recruiting	Collaborator	Fox Chase Cancer Center	—	Lymphoma; Indolent Non-hodgkin Lymphoma	—
NCT06252675	Phase 2	Recruiting	Collaborator	University of California, San Francisco	LLY	Mantle Cell Lymphoma	—
NCT06828991	Phase 2	Recruiting	Collaborator	Danielle Wallace	—	Diffuse Large B-Cell Lymphoma (DLBCL)	—
NCT07151950	Not disclosed	Active, not recruiting	Collaborator	Desin LLC	—	Upper Extremity Impairments; Cerebral Palsy (CP); ALS - Amyotrophic Lateral Sclerosis	—
NCT05271630	Not disclosed	Active, not recruiting	Collaborator	H. Lee Moffitt Cancer Center and Research Institute	—	Multiple Myeloma	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 7 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 10 active trials for Global Coalition for Adaptive Research on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ADPT — Adaptive Biotechnologies Corporation